Apnea obstructiva del sueño

1. Morrone E, Giordano A, Carli S, et al. Something is changing in adherence to CPAP therapy: real world data after 1 year of treatment in patients with obstructive sleep apnoea. Eur Respir J 2020; 55(3):1901419. doi:10.1183/13993003.01419-2019

2. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defi ning phenotypic causes of obstructive sleep apnea. Identifi cation of novel therapeutic targets. Am J Respir Crit Care Med 2013; 188(8):996– 1004. doi:10.1164/rccm.201303-0448OC

3. Zinchuk A, Yaggi HK. Phenotypic subtypes of OSA: a challenge and opportunity for precision medicine. Chest 2020; 157(2):403–420. doi:10.1016/j.chest.2019.09.002

4. American Academy of Sleep Medicine. International Classifi cation of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.

5. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 177(9):1006–1014. doi:10.1093/aje/kws342

6. Bonsignore MR, Pepin JL, Cibella F, et al. Excessive daytime sleepiness in obstructive sleep apnea patients treated with continuous positive airway pressure: data from the European Sleep Apnea Database. Front Neurol 2021; 12:690008. doi:10.3389/fneur.2021.690008

7. Pocobelli G, Akosile MA, Hansen RN, et al. Obstructive sleep apnea and risk of motor vehicle accident. Sleep Med 2021; 85:196–203. doi:10.1016/j.sleep.2021.07.019

8. Cai A, Wang L, Zhou Y. Hypertension and obstructive sleep apnea. Hypertens Res 2016; 39(6):391–395. doi:10.1038/hr.2016.11

9. Kendzerska T, Gershon AS, Hawker G, Tomlinson G, Leung RS. Obstructive sleep apnea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med 2014; 190(2):218–225.doi:10.1164/rccm.201312-2209OC Downloaded

10. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365(9464):1046–1053.doi:10.1016/S0140-6736(05)71141-7

11. Lal C, Ayappa I, Ayas N, et al. The link between obstructive sleep apnea and neurocognitive impairment: an offi cial American Thoracic Society Workshop report. Ann Am Thorac Soc 2022; 19(8):1245–1256. doi:10.1513/AnnalsATS.202205-380ST

12. Patel A, Chong DJ. Obstructive sleep apnea: cognitive outcomes. Clin Geriatr Med 2021; 37(3):457–467. doi:10.1016/j.cger.2021.04.007

13. Cartwright RD. Effect of sleep position on sleep apnea severity. Sleep 1984; 7(2):110–114. doi:10.1093/sleep/7.2.110

14. Srijithesh PR, Aghoram R, Goel A, Dhanya J. Positional therapy for obstructive sleep apnoea. Cochrane Database Syst Rev 2019; 5(5):CD010990. doi:10.1002/14651858.CD010990.pub2

15. Randerath W, Verbraecken J, de Raaff CAL, et al. European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea. Eur Respir Rev 2021; 30(162):210200.doi:10.1183/16000617.0200-2021

16. Taranto-Montemurro L, Messineo L, Azarbarzin A, et al. Effects of the combination of atomoxetine and oxybutynin on OSA endotypic traits. Chest 2020; 157(6):1626–1636.doi:10.1016/j.chest.2020.01.012

17. Mehta V, Vasu TS, Phillips B, Chung F. Obstructive sleep apnea and oxygen therapy: a systematic review of the literature and meta-analysis. J Clin Sleep Med 2013; 9(3):271–279. doi:10.5664/jcsm.2500

18. Sands SA, Edwards BA, Terrill PI, et al. Identifying obstructive sleep apnoea patients responsive to supplemental oxygen therapy. Eur Respir J 2018; 52(3):1800674. doi:10.1183/13993003.00674-2018

19. Vecchierini MF, Attali V, Collet JM, et al. Mandibular advancement device use in obstructive sleep apnea: ORCADES study 5-year follow- up data. J Clin Sleep Med 2021; 17(8):1695–1705. doi:10.5664/jcsm.9308

20. Camacho M, Certal V, Abdullatif J, et al. Myofunctional therapy to treat obstructive sleep apnea: a systematic review and meta-analysis. Sleep 2015; 38(5):669–675. doi:10.5665/sleep.4652

21. Joosten SA, Tan M, Wong AM, et al. A randomized controlled trial of oxygen therapy for patients who do not respond to Upper airway surgery for obstructive sleep apnea. J Clin Sleep Med 2021; 17(3):445–452. doi:10.5664/jcsm.8920

22. Chen H, Eckert DJ, van der Stelt PF, et al. Phenotypes of responders to mandibular advancement device therapy in obstructive sleep apnea patients: a systematic review and meta-analysis. Sleep Med Rev 2020; 49:101229. doi:10.1016/j.smrv.2019.101229

23. Prasad KT, Sehgal IS, Agarwal R, Nath Aggarwal A, Behera D, Dhooria S. Assessing the likelihood of obstructive sleep apnea: a comparison of nine screening questionnaires. Sleep Breath 2017; 21(4):909–917. doi:10.1007/s11325-017-1495-4

24. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284(23):3015–3021. doi:10.1001/jama.284.23.3015

25. Schwartz AR, Gold AR, Schubert N, et al. Effect of weight loss on upper airway collapsibility in obstructive sleep apnea. Am Rev Respir Dis 1991; 144(3 Pt 1):494–498. doi:10.1164/ajrccm/144.3_Pt_1.494

26. Kuna ST, Reboussin DM, Strotmeyer ES, et al. Effects of weight los on obstructive sleep apnea severity. Ten-year results of the sleep AHEAD study. Am J Respir Crit Care Med 2021; 203(2):221–229. doi:10.1164/rccm.201912-2511OC

27. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis [published correction appears in JAMA 2005; 293(14):1728]. JAMA 2004; 292(14):1724–1737. doi:10.1001/jama.292.14.1724

28. Nastałek P, Polok K, Celejewska-Wojcik N, et al. Impact of bariatric surgery on obstructive sleep apnea severity and continuous positive airway pressure therapy compliance—prospective observational study. Sci Rep 2021; 11(1):5003. doi:10.1038/s41598-021-84570-6

29. Peromaa-Haavisto P, Tuomilehto H, Kossi J, et al. Obstructive sleep apnea: the effect of bariatric surgery after 12 months. A prospective multicenter trial. Sleep Med 2017; 35:85–90. doi:10.1016/j.sleep.2016.12.017

30. Dixon JB, Schachter LM, O’Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 308(11):1142–1149. doi:10.1001/2012.jama.11580

31. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016; 40(8):1310–1319. doi:10.1038/ijo.2016.52

32. Sultana R, Sissoho F, Kaushik VP, Raji MA. The case for early use of glucagon-like peptide-1 receptor agonists in obstructive sleep apnea patients with comorbid diabetes and metabolic syndrome. Life (Basel) 2022; 12(8):1222. doi:10.3390/life12081222

33. Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther 2021; 38(6):2821–2839. doi:10.1007/s12325-021-01710-0

34. Iftikhar IH, Kline CE, Youngstedt SD. Effects of exercise training on sleep apnea: a meta-analysis. Lung 2014; 192(1):175–184. doi:10.1007/s00408-013-9511-3

35. Kline CE, Reboussin DM, Foster GD, et al. The effect of changes in cardiorespiratory fi tness and weight on obstructive sleep apnea severity in overweight adults with type 2 diabetes. Sleep 2016; 39(2):317–325. doi:10.5665/sleep.5436

36. Ozeke O, Erturk O, Gungor M, et al. Infl uence of the right- versus left-sided sleeping position on the apnea-hypopnea index in patients with sleep apnea. Sleep Breath 2012; 16(3):617–620. doi:10.1007/s11325-011-0547-4

37. Pevernagie DA, Stanson AW, Sheedy PF 2nd, Daniels BK, Shepard JW Jr. Effects of body position on the upper airway of patients with obstructive sleep apnea. Am J Respir Crit Care Med 1995; 152(1):179–185. doi:10.1164/ajrccm.152.1.7599821

38. Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of sleep apnoea: a systematic review and meta-analysis. Sleep Med 2018; 42:38–46. doi:10.1016/j.sleep.2017.12.005

39. Kolla BP, Foroughi M, Saeidifard F, Chakravorty S, Wang Z, Mansukhani MP. The impact of alcohol on breathing parameters during sleep: a systematic review and meta-analysis. Sleep Med Rev 2018; 42:59–67. doi:10.1016/j.smrv.2018.05.007

40. Burgos-Sanchez C, Jones NN,  villion M, et al. Impact of alcohol consumption on snoring and sleep apnea: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 2020; 163(6):1078–1086. doi:10.1177/0194599820931087

41. Krol RC, Knuth SL, Bartlett D Jr. Selective reduction of genioglossal muscle activity by alcohol in normal human subjects. Am Rev Respir Dis 1984; 129(2):247–250. pmid:6421210

42. St John WM, Bartlett D Jr, Knuth KV, Knuth SL, Daubenspeck JA. Differential depression of hypoglossal nerve activity by alcohol. Protection by pretreatment with medroxyprogesterone acetate. Am Rev Respir Dis 1986; 133(1):46–48. doi:10.1164/arrd.1986.133.1.46

43. Mason M, Welsh EJ, Smith I. Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2013;(5):CD003002. doi:10.1002/14651858.CD003002.pub3

44. Brownell LG, West P, Sweatman P, Acres JC, Kryger MH. Protriptyline in obstructive sleep apnea: a double-blind trial. N Engl J Med 1982; 307(17):1037–1042.

doi:10.1056/NEJM198210213071701

45. Hanzel DA, Proia NG, Hudgel DW. Response of obstructive sleep apnea to fl uoxetine and protriptyline. Chest 1991; 100(2):416–421. doi:10.1378/chest.100.2.416

46. Eskandari D, Zou D, Grote L, Hoff E, Hedner J. Acetazolamide reduces blood pressure and sleep-disordered breathing in patients with hypertension and obstructive sleep apnea: a randomized controlled trial. J Clin Sleep Med 2018; 14(3):309–317. doi:10.5664/jcsm.6968

47. Edwards BA, Sands SA, Eckert DJ, et al. Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea. J Physiol 2012; 590(5):1199–1211. doi:10.1113/jphysiol.2011.223925

48. Taranto-Montemurro L, Messineo L, Sands SA, et al. The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. a randomized, placebo-controlled, double-blind crossover trial. Am J Respir Crit Care Med 2019; 199(10):1267–1276. doi:10.1164/rccm.201808-1493OC

49. Perger E, Taranto-Montemurro L, Rosa D, et al. Reboxetine plus oxybutynin for OSA treatment: a 1-week, randomized, placebo-controlled, double-blind crossover trial. Chest 2022; 161(1):237–247. doi:10.1016/j.chest.2021.08.080

50. Messineo L, Taranto-Montemurro L, Calianese N, et al. Atomoxetine and fesoterodine combination improves obstructive sleep apnoea severity in patients with milder upper airway collapsibility. Respirology 2022; 27(11):975–982. doi:10.1111/resp.14326

51. Gottlieb DJ, Punjabi NM, Mehra R, et al. CPAP versus oxygen in obstructive sleep apnea. N Engl J Med 2014; 370(24):2276–2285. doi:10.1056/NEJMoa1306766

52. Chan AS, Sutherland K, Schwab RJ, et al. The effect of mandibular advancement on upper airway structure in obstructive sleep apnoea. Thorax 2010; 65(8):726–732. doi:10.1136/thx.2009.131094

53. Trzepizur W, Cistulli PA, Glos M, et al. Health outcomes of continuous positive airway pressure versus mandibular advancement device for the treatment of severe obstructive sleep apnea: an individual participant data meta-analysis. Sleep 2021; 44(7):zsab015. doi:10.1093/sleep/zsab015

54. Levine M, Cantwell MK, Postol K, Schwartz DB. Dental sleep medicine standards for screening, treatment, and management of sleep-related breathing disorders in adults using oral appliance therapy: an update. J Dent Sleep Med 2022; 9(4):1–13. doi:10.15331/jdsm.7266

55. Sutherland K, Phillips CL, Davies A, et al. CPAP pressure for prediction of oral appliance treatment response in obstructive sleep apnea. J Clin Sleep Med 2014; 10(9):943–949. doi:10.5664/jcsm.4020

56. de Vries GE, Wijkstra PJ, Houwerzijl EJ, Kerstjens HAM, Hoekema A. Cardiovascular effects of oral appliance therapy in obstructive sleep apnea: a systematic review and meta-analysis. Sleep Med Rev 2018; 40:55–68. doi:10.1016/j.smrv.2017.10.004

57. Rietz H, Franklin KA, Carlberg B, Sahlin C, Marklund M. Nocturnal blood pressure is reduced by a mandibular advancement device for sleep apnea in women: fi ndings from secondary analyses of a randomized trial. J Am Heart Assoc 2018; 7(13):e008642. doi:10.1161/JAHA.118.008642

58. Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 2004; 27(5):934–941. doi:10.1093/sleep/27.5.934

59. Tegelberg A, Wilhelmsson B, Erixon-Lindroth N, Lindstrom LH. Improved cognitive functions after treatment with an oral appliance in obstructive sleep apnea. Nat Sci Sleep 2012; 4:89–96. doi:10.2147/NSS.S33849

60. Baptista PM, Martinez Ruiz de Apodaca P, Carrasco M, et al. Daytime neuromuscular electrical therapy of tongue muscles in improving snoring in individuals with primary snoring and mild obstructive sleep apnea. J Clin Med 2021; 10(9):1883. doi:10.3390/jcm10091883